Loading financials from SEC filings…
Semiconductors · Technology · Fiscal year ends Jan 2
Silicon Laboratories reported revenue of $785M in the fiscal year ended Jan 2026, up 34.3% from the year before. Operating income was −$71M, an operating margin of −9.0%, and net income was −$65M. Operating cash flow of $96M less capital expenditure of $30M left free cash flow of $66M.
Ranks among the 51 semiconductors companies we cover (1st = best; for debt, the least indebted). Green = top third, red = bottom third.
Last 5 fiscal years
| Fiscal year | Jan 2022 | Dec 2022 | Dec 2023 | Dec 2024 | Jan 2026 |
|---|---|---|---|---|---|
| Revenue | 721 | 1,024 | 782 | 584 | 785 |
| Cost of revenue | 295 | 382 | 322 | 272 | 328 |
| Gross profit | 425 | 643 | 461 | 312 | 457 |
| Research & development | 273 | 332 | 338 | 332 | 353 |
| Selling, general & admin | 185 | 191 | 147 | 145 | 174 |
| Operating income | −32.8 | 119 | −24.2 | −165 | −70.5 |
| Interest expense | 31.0 | 6.7 | 5.6 | 1.3 | 1.0 |
| Pre-tax income | −44.4 | 130 | −26.6 | −155 | −57.9 |
| Income tax | 13.4 | 38.5 | 7.9 | 36.2 | 7.0 |
| Net income | 2,117 | 91.4 | −34.5 | −191 | −64.9 |
| Diluted EPS | 47.78 | 2.54 | −1.09 | −5.93 | −1.98 |
| Diluted shares | 44.3 | 36.0 | 31.8 | 32.2 | 32.7 |
| Fiscal year | Jan 2022 | Dec 2022 | Dec 2023 | Dec 2024 | Jan 2026 |
|---|---|---|---|---|---|
| Cash & equivalents | 1,075 | 500 | 228 | 282 | 364 |
| Receivables | 98.3 | 71.4 | 29.3 | 54.5 | 64.5 |
| Inventory | 49.3 | 100 | 194 | 106 | 95.6 |
| Current assets | 2,239 | 1,461 | 738 | 602 | 674 |
| Net PP&E | 147 | 152 | 146 | 132 | 129 |
| Goodwill | 376 | 376 | 376 | 376 | 376 |
| Total assets | 2,958 | 2,169 | 1,443 | 1,223 | 1,269 |
| Payables | 47.3 | 89.9 | 57.5 | 42.4 | 50.7 |
| Current liabilities | 669 | 186 | 164 | 97.9 | 144 |
| Total liabilities | 746 | 764 | 234 | 143 | 175 |
| Shareholders' equity | 2,212 | 1,405 | 1,209 | 1,080 | 1,094 |
| Fiscal year | Jan 2022 | Dec 2022 | Dec 2023 | Dec 2024 | Jan 2026 |
|---|---|---|---|---|---|
| Operating cash flow | 91.2 | 141 | −30.3 | −13.9 | 95.7 |
| Capital expenditure | 28.6 | 26.5 | 22.3 | 11.7 | 29.9 |
| Free cash flow | 62.6 | 115 | −52.6 | −25.7 | 65.8 |
| Depreciation & amortisation | 18.1 | 22.5 | 25.7 | 25.6 | 24.7 |
| Stock-based compensation | 56.8 | 60.5 | 48.2 | 61.5 | 80.3 |
| Share buybacks | 1,150 | 883 | 217 | 0.0 | 0.0 |
| Fiscal year | Jan 2022 | Dec 2022 | Dec 2023 | Dec 2024 | Jan 2026 |
|---|---|---|---|---|---|
| Revenue growth (YoY) | – | 42.1% | −23.6% | −25.3% | 34.3% |
| Operating income growth (YoY) | – | – | −120.3% | – | – |
| EPS growth (YoY) | – | −94.7% | −142.9% | – | – |
| Gross margin | 59.0% | 62.7% | 58.9% | 53.4% | 58.2% |
| Operating margin | −4.6% | 11.6% | −3.1% | −28.3% | −9.0% |
| Net margin | 293.7% | 8.9% | −4.4% | −32.7% | −8.3% |
| Return on equityBlank when equity is negative | 95.7% | 6.5% | −2.9% | −17.7% | −5.9% |
| ROCEEBIT ÷ (assets − current liabilities) | −1.4% | 6.0% | −1.9% | −14.7% | −6.3% |
| Free cash flow margin | 8.7% | 11.2% | −6.7% | −4.4% | 8.4% |
| Cash conversion (CFO ÷ net income) | 0.04x | 1.55x | 0.88x | 0.07x | −1.47x |
| Receivable days | 50 | 25 | 14 | 34 | 30 |
| Inventory days | 61 | 96 | 220 | 142 | 106 |
| Payable days | 58 | 86 | 65 | 57 | 56 |
| Interest cover | −1.06x | 17.7x | −4.35x | −126x | −72.3x |
| Current ratio | 3.35x | 7.87x | 4.51x | 6.15x | 4.69x |
Standardised figures from the company's XBRL filings with the SEC (10-K, 10-Q). Line items follow US GAAP tags, so a company's own statement layout may differ and some lines show “–” where the company does not report that item. Ratios are calculated from these figures. For education only; not investment advice or a recommendation.